The investment seeks the balanced accomplishment of three objectives: long-term growth of capital, conservation of principal and current income... Show more
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Category ModerateAllocation
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| FSBDX | 27.62 | 0.56 | +2.07% |
| Fidelity Series Blue Chip Growth | |||
| GGQPX | 22.89 | 0.19 | +0.84% |
| Goldman Sachs Mid Cap Growth P | |||
| PIVYX | 45.87 | 0.25 | +0.55% |
| Putnam International Small Cap Y | |||
| FHCIX | 64.57 | 0.17 | +0.26% |
| Fidelity Advisor Health Care I | |||
| LDVCX | 21.86 | -0.05 | -0.23% |
| AXS FTSE Vntr Cptl RetTrckr C | |||
A.I.dvisor indicates that over the last year, GBLEX has been closely correlated with CIBFX. These tickers have moved in lockstep 96% of the time. This A.I.-generated data suggests there is a high statistical probability that if GBLEX jumps, then CIBFX could also see price increases.
| Ticker / NAME | Correlation To GBLEX | 1D Price Change % | ||
|---|---|---|---|---|
| GBLEX | 100% | +0.39% | ||
| CIBFX - GBLEX | 96% Closely correlated | N/A | ||
| CIBCX - GBLEX | 96% Closely correlated | N/A | ||
| RIRCX - GBLEX | 95% Closely correlated | N/A | ||
| CIREX - GBLEX | 95% Closely correlated | N/A | ||
| CIRAX - GBLEX | 95% Closely correlated | N/A | ||
More | ||||